2020 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
*Purpose: Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of HCV has shifted in the last few…2020 American Transplant Congress
Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased…2020 American Transplant Congress
Association between Ezetimibe Usage and Hepatitis C RNA Levels in Uninfected Kidney Transplant Recipients Who Received Hepatitis C Infected Kidneys
James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN
*Purpose: Our previous data showed that transplantation of kidneys from hepatitis C virus (HCV) infected donors to HCV negative recipients achieved excellent short-term graft function,…2020 American Transplant Congress
Single Center Experience of Valganciclovir and Adjunctive CMV IVIG for the Treatment of CMV Infection in Lung Transplant Recipients
*Purpose: Cytomegalovirus(CMV) infection happens commonly and causes significant morbidity in lung transplant (LTx) recipients. The use of CMV hyperimmune globulin (CMVIg) as an adjunctive treatment…2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…2020 American Transplant Congress
Access to Direct Acting Antiviral Therapy for Recipients of Solid Organs from Hepatitis C Viremic Donors
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Emerging data supports transplantation of organs from hepatitis C-positive (HCV) donors to expand the donor pool, but access to direct acting antivirals (DAAs) to…2020 American Transplant Congress
Pharmacy Led Initiatives for Treatment of Transplant Recipients of Hepatitis C Viremic Donors in a High Volume Transplant Center
Duke University Medical Center, Durham, NC
*Purpose: We describe a multidisciplinary workflow for initiation of hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies post-transplant in the outpatient setting of a high…2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…2020 American Transplant Congress
Use of Letermovir for Cytomegalovirus Management in Thoracic Organ Transplantation
Duke University Medical Center, Durham, NC
*Purpose: Cytomegalovirus (CMV) commonly affects thoracic solid organ transplant (SOT) recipients, and standard antiviral therapies are limited by myelosuppression, renal dysfunction, and emergence of resistance.…2020 American Transplant Congress
Experience with a BKV-Specific, Neutralizing Monoclonal Antibody (MAU868) for Treatment of Severe BK Virus Nephropathy (BKVN) after Kidney Transplant (FDA EIND #139112)
*Purpose: BK viral reactivation leading to nephropathy and allograft loss in kidney transplant recipients remains a significant challenge. No effective BKV-therapies are currently available. Management…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 14
- Next Page »